In the last trading session, 2.31 million VistaGen Therapeutics Inc (NASDAQ:VTGN) shares changed hands as the company’s beta touched 0.72. With the company’s per share price at $3.38 changed hands at $0.06 or 1.81% during last session, the market valuation stood at $91.33M. VTGN’s last price was a discount, traded about -631.07% off its 52-week high of $24.71. The share price had its 52-week low at $1.62, which suggests the last value was 52.07% up since then. When we look at VistaGen Therapeutics Inc’s average trading volume, we note the 10-day average is 0.79 million shares, with the 3-month average coming to 608.23K.
VistaGen Therapeutics Inc (NASDAQ:VTGN) trade information
Instantly VTGN was in green as seen at the end of in last trading. With action 31.52%, the performance over the past five days has been green. The jump to weekly highs of 3.61 on Friday, 11/17/23 added 1.81% to the stock’s daily price. The company’s shares are showing year-to-date upside of 9.39%, with the 5-day performance at 31.52% in the green. However, in the 30-day time frame, VistaGen Therapeutics Inc (NASDAQ:VTGN) is 12.29% up. Looking at the short shares, we see there were 1.55 million shares sold at short interest cover period of 2.18 days.
VistaGen Therapeutics Inc (VTGN) estimates and forecasts
Data shows that the VistaGen Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -18.06% over the past 6 months, a 74.74% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for VistaGen Therapeutics Inc will rise 86.20%, while the growth in revenue is estimated to hit 68.70% for the next quarter.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of $750k. The company’s revenue for the corresponding quarters a year ago was $180k and $176k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 316.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 24.01%. The 2023 estimates are for VistaGen Therapeutics Inc earnings to increase by 76.85%.
VistaGen Therapeutics Inc is expected to release its next quarterly earnings report between February 05 and February 09.
VistaGen Therapeutics Inc (NASDAQ:VTGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.79% of VistaGen Therapeutics Inc shares while 11.44% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 11.53%. There are 11.44% institutions holding the VistaGen Therapeutics Inc stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 2.39% of the shares, roughly 0.22 million VTGN shares worth $0.42 million.
Gsa Capital Partners Llp holds the second largest percentage of outstanding shares, with 2.12% or 0.2 million shares worth $0.37 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 0.14 million shares estimated at $0.25 million under it, the former controlled 1.44% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.86% of the shares, roughly 80762.0 shares worth around $0.15 million.